| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America HW Boucher, GH Talbot, JS Bradley, JE Edwards, D Gilbert, LB Rice, ... Clinical infectious diseases 48 (1), 1-12, 2009 | 6193 | 2009 |
| The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America B Spellberg, R Guidos, D Gilbert, J Bradley, HW Boucher, WM Scheld, ... Clinical infectious diseases 46 (2), 155-164, 2008 | 2123 | 2008 |
| Novel perspectives on mucormycosis: pathophysiology, presentation, and management B Spellberg, J Edwards Jr, A Ibrahim Clinical microbiology reviews 18 (3), 556-569, 2005 | 1620 | 2005 |
| Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group … OA Cornely, A Alastruey-Izquierdo, D Arenz, SCA Chen, E Dannaoui, ... The Lancet infectious diseases 19 (12), e405-e421, 2019 | 1389 | 2019 |
| Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles LG Miller, F Perdreau-Remington, G Rieg, S Mehdi, J Perlroth, AS Bayer, ... New England Journal of Medicine 352 (14), 1445-1453, 2005 | 1368 | 2005 |
| Type 1/Type 2 immunity in infectious diseases B Spellberg, JE Edwards Jr Clinical Infectious Diseases 32 (1), 76-102, 2001 | 1244 | 2001 |
| Trends in antimicrobial drug development: implications for the future B Spellberg, JH Powers, EP Brass, LG Miller, JE Edwards Jr Clinical infectious diseases 38 (9), 1279-1286, 2004 | 1203 | 2004 |
| Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges D Wong, TB Nielsen, RA Bonomo, P Pantapalangkoor, B Luna, ... Clinical microbiology reviews 30 (1), 409-447, 2017 | 1012 | 2017 |
| Nosocomial fungal infections: epidemiology, diagnosis, and treatment J Perlroth, B Choi, B Spellberg Medical mycology 45 (4), 321-346, 2007 | 933 | 2007 |
| Pathogenesis of mucormycosis AS Ibrahim, B Spellberg, TJ Walsh, DP Kontoyiannis Clinical infectious diseases 54 (suppl_1), S16-S22, 2012 | 824 | 2012 |
| The future of antibiotics and resistance B Spellberg, JG Bartlett, DN Gilbert New England Journal of Medicine 368 (4), 299-302, 2013 | 802 | 2013 |
| Novel antipsychotics and new onset diabetes DA Wirshing, BJ Spellberg, SM Erhart, SR Marder, WC Wirshing Biological psychiatry 44 (8), 778-783, 1998 | 675 | 1998 |
| Seven ways to preserve the miracle of antibiotics JG Bartlett, DN Gilbert, B Spellberg Clinical infectious diseases 56 (10), 1445-1450, 2013 | 668 | 2013 |
| Recent advances in the management of mucormycosis: from bench to bedside EJC Goldstein, B Spellberg, TJ Walsh, DP Kontoyiannis, J Edwards Jr, ... Clinical Infectious Diseases 48 (12), 1743-1751, 2009 | 595 | 2009 |
| Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis C Reed, R Bryant, AS Ibrahim, J Edwards Jr, SG Filler, R Goldberg, ... Clinical Infectious Diseases 47 (3), 364-371, 2008 | 555 | 2008 |
| Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice L Lin, AS Ibrahim, X Xu, JM Farber, V Avanesian, B Baquir, Y Fu, ... PLoS pathogens 5 (12), e1000703, 2009 | 515 | 2009 |
| Systemic antibiotic therapy for chronic osteomyelitis in adults B Spellberg, BA Lipsky Clinical infectious diseases 54 (3), 393-407, 2012 | 495 | 2012 |
| The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett B Spellberg, DN Gilbert Clinical infectious diseases 59 (suppl_2), S71-S75, 2014 | 462 | 2014 |
| The iron chelator deferasirox protects mice from mucormycosis through iron starvation AS Ibrahim, T Gebermariam, Y Fu, L Lin, MI Husseiny, SW French, ... The Journal of clinical investigation 117 (9), 2649-2657, 2007 | 356 | 2007 |
| Current treatment strategies for disseminated candidiasis BJ Spellberg, SG Filler, JE Edwards Jr Clinical Infectious Diseases 42 (2), 244-251, 2006 | 351 | 2006 |
